BioAtla (NASDAQ:BCAB) Releases Earnings Results

BioAtla (NASDAQ:BCAB) announced its quarterly earnings data on Tuesday. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.20, FiscalAI reports. The firm had revenue of $2.00 million during the quarter, compared to analysts’ expectations of $0.70 million.

BioAtla Price Performance

BCAB stock opened at $0.13 on Thursday. BioAtla has a 1-year low of $0.12 and a 1-year high of $1.43. The business has a 50 day simple moving average of $0.20 and a two-hundred day simple moving average of $0.53. The company has a market capitalization of $8.54 million, a price-to-earnings ratio of -0.13 and a beta of 1.22.

Hedge Funds Weigh In On BioAtla

Several hedge funds have recently modified their holdings of the stock. Woodline Partners LP bought a new position in shares of BioAtla during the first quarter worth $26,000. ADAR1 Capital Management LLC bought a new stake in BioAtla in the 4th quarter valued at $104,000. Susquehanna International Group LLP lifted its stake in BioAtla by 237.6% in the 3rd quarter. Susquehanna International Group LLP now owns 252,583 shares of the company’s stock worth $174,000 after purchasing an additional 177,760 shares in the last quarter. Jane Street Group LLC lifted its stake in BioAtla by 55.4% in the 4th quarter. Jane Street Group LLC now owns 346,774 shares of the company’s stock worth $197,000 after purchasing an additional 123,597 shares in the last quarter. Finally, Millennium Management LLC bought a new position in shares of BioAtla during the 3rd quarter valued at about $235,000. Hedge funds and other institutional investors own 77.23% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on BCAB shares. Rodman & Renshaw started coverage on shares of BioAtla in a research note on Tuesday, January 13th. They set a “buy” rating and a $4.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of BioAtla in a report on Friday, January 9th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $4.00.

About BioAtla

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.